VANCOUVER, Canada, July 13 -- Sirius Genomics, a developer of pharmacogenomic
diagnostics, announced today that it has signed a collaborative agreement with
the Assistance Publique-Hopitaux de Paris (AP-HP) to study genomic correlations
in severe sepsis patients. The agreement focuses on the continued development of
Sirius’ pharmacogenomic diagnostic intended to assess responsiveness to
recombinant human activated Protein C (sold by Eli Lilly and Company under the
trademark Xigris (R)) in patients with severe sepsis at high risk of death.

Access to AP-HP’s severe sepsis patients will be critical in the
validation of Sirius’ sepsis biomarkers and we are delighted to be working
with this internationally acclaimed research group, commented Dr. Brad Popovich,
President and CEO of Sirius Genomics.

We are pleased to be a part of this research effort because working with Sirius
Genomics will help translate genomic biomarker research in sepsis from the lab
bench to the patient bedside, stated Professor Djillali Annane, the Principal
Investigator behind two clinical studies that will be utilized in the new

Financial terms of the agreement were not disclosed.

About Assistance Publique-Hopitaux de Paris:

The Assistance Publique - Hôpitaux de Paris is a public health establishment
in Paris, France with activities in the field of healthcare, teaching, medical
research, prevention, health education, and urgent medical assistance. The AP-HP
consists of a 37 hospitals group, and home nursing. It offers patient care based
on every diagnostic and therapeutic possibility: all specialists medical areas,
structured around 720 medical departments, are represented. It is linked to 7
faculties of medicine, 2 dentistry faculties and 2 pharmacy faculties. The
Clinical Research and Development Department (DRCD) of the AP-HP coordinates
more than 2000 clinical trials, institutional and industrial sponsorships

About Sirius Genomics:

Sirius Genomics is a drug-enabling company that develops pharmacogenomic (PGx)
diagnostics that lead to better patient outcomes through personalized medicine.
Sirius generates value by improving the safety and effectiveness of
pharmaceutical compounds. The Company correlates patient genetics with clinical
outcomes, leading to proprietary and commercially viable PGx products that
enable better drug treatment. The Company’s first product is a genetic
predictor of response to treatment for sepsis, a severe blood infection.

This release contains forward-looking statements that are not based on
historical fact. These forward-looking statements involve risks, uncertainties
and other factors that may cause the actual results, events or developments to
be materially different from those expressed or implied by such forward-looking
statements. Readers are cautioned not to place undue reliance on such
forward-looking statements.

For further information: Dr. Brad Popovich, President and CEO, Sirius Genomics,

SOURCE: Sirius Genomics Inc.

For further information: Dr. Brad Popovich, President and CEO, Sirius Genomics,